Can HMGI-C be used as an aid with MDM2 and CDK4 to differentiate liposarcoma subtypes from their mimics?
- PMID: 23529275
- PMCID: PMC11824795
- DOI: 10.1007/s00432-013-1420-6
Can HMGI-C be used as an aid with MDM2 and CDK4 to differentiate liposarcoma subtypes from their mimics?
Abstract
Purpose: Liposarcoma represents the most common soft tissue tumors in adults. The tumors are characterized by a high morphological diversity and a great variation in biological behavior. Atypical lipomatous tumors represent a distinctive subset of mesenchymal neoplasms featuring mature adipocytic differentiation. Histologically, atypical lipomatous tumor might be easily confused with lipoma. Conversely, dedifferentiated liposarcoma may be confused with other spindle cell/pleomorphic undifferentiated tumors.
Methods: A group of liposarcomas was analyzed by investigating the MDM2, CDK4, and HMGI-C proteins. The study was extended to a group of lipomas and non-lipomatous sarcomas, to determine whether the immunohistochemical investigation of these proteins might play any diagnostic role.
Results: Our data suggest that ordinary lipomas may form a molecular genetic and morphological continuum with atypical lipomatous tumor. At one end of the spectrum are lipomas characterized by HMGI-C activation and at the other end are atypical lipomatous tumors with overrepresentation of the HMGI-C, CDK4, or MDM2 proteins. These findings not only provide insights into the molecular pathogenesis of lipomatous tumors, but also indicate that the immunohistochemical analysis of HMGI-C, CDK4, or MDM2 may help to increase diagnostic accuracy.
Conclusions: HMGI-C is a useful adjunct in the diagnosis of atypical lipomatous tumor and dedifferentiated liposarcoma and differentiates them from their mimics. Therefore, in our experience, HMGI-C expression alone is of rather limited value in the differential diagnosis of liposarcoma subtypes.
Figures



Similar articles
-
Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours.J Pathol. 2000 Apr;190(5):531-6. doi: 10.1002/(SICI)1096-9896(200004)190:5<531::AID-PATH579>3.0.CO;2-W. J Pathol. 2000. PMID: 10727978
-
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21. Clin Orthop Relat Res. 2025. PMID: 38905450
-
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887. Elife. 2025. PMID: 40407808 Free PMC article.
-
Diagnostic and management challenges for MDM2-, CDK4-negative fatty tumors of the retroperitoneum.J Cancer Res Clin Oncol. 2021 Apr;147(4):1137-1144. doi: 10.1007/s00432-021-03512-x. Epub 2021 Feb 6. J Cancer Res Clin Oncol. 2021. PMID: 33550433 Free PMC article. Review.
-
Atypical lipomatous tumor/well differentiated liposarcoma and related mimics with updates. When is molecular testing most cost-effective, necessary, and indicated?Hum Pathol. 2024 May;147:82-91. doi: 10.1016/j.humpath.2023.12.005. Epub 2023 Dec 21. Hum Pathol. 2024. PMID: 38135062 Review.
Cited by
-
Expression of FRS2 in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: an immunohistochemical analysis of 182 cases with genetic data.Diagn Pathol. 2021 Oct 25;16(1):96. doi: 10.1186/s13000-021-01161-9. Diagn Pathol. 2021. PMID: 34696768 Free PMC article.
-
Application of adipocyte-related antibodies in undifferentiated sarcomas to identify dedifferentiated liposarcomas based on histological and clinical analysis.Int J Clin Exp Pathol. 2018 Apr 1;11(4):2246-2255. eCollection 2018. Int J Clin Exp Pathol. 2018. PMID: 31938337 Free PMC article.
-
Retroperitoneal liposarcoma: current insights in diagnosis and treatment.Front Surg. 2015 Feb 10;2:4. doi: 10.3389/fsurg.2015.00004. eCollection 2015. Front Surg. 2015. PMID: 25713799 Free PMC article. Review.
References
-
- Alexio PB, Hartmann AA, Menezes IC, Meurer RT, Olivera AM (2009) Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study of 129 soft tissue tumours. J Clin Pathol 62:1127–1135 - PubMed
-
- Angelo P, Dei T, Claudio D, Sara P, Raf S, Alberto F, Mauro B, Paola DC, Roberta M, Fletcher CDM, Giovanni T (2000) Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 190:531–536 - PubMed
-
- Antoine I, Laurence B, Elisabet G et al (2009) Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 15:5696–5703 - PubMed
-
- Binh MB, Sastre-Garau X, Guillou L et al (2005) MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 29:1340–1344 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials